Date: 2018-05-30
Type of information: Development agreement
Compound: immunohistochemistry (IHC) companion diagnostic assays for use with bemarituzumab (FPA144), and FPA150
Company: Five Prime Therapeutics (USA - CA) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: companion diagnostic
Disease: tumors overexpressing FGFR2b
Details:
- • On May 30, 2018, Five Prime Therapeutics announced it has entered into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime’s first-in-class investigational
drug candidates, bemarituzumab, an anti-FGFR2b antibody (also known as FPA144), and FPA150, a B7-H4 antibody.
- Five Prime and Roche are collaborating to develop, validate and commercialize a tissue-based IHC companion diagnostic (CDx) assay to help identify patients whose tumors overexpress FGFR2b and are eligible for treatment with bemarituzumab. The CDx assay will be used in Five Prime’s global registrational study of bemarituzumab in combination with 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, a regimen known as mFOLFOX6, as front-line treatment in patients with advanced gastric or gastroesophageal junction cancer whose tumors overexpress FGFR2b or have FGFR2 gene amplification (the FIGHT trial) that Five Prime expects to start in the second half of 2018.
- Five Prime plans to use the Roche IHC assay along with a
circulating tumor DNA (ctDNA) test in the FIGHT trial to identify the estimated 10 percent of patients with gastric and gastroesophageal junction cancer who would be eligible for treatment with bemarituzumab.
- Five Prime and Roche will also collaborate to develop and validate a tissue-based IHC diagnostic assay for use as a laboratory developed test (LDT) to help identify patients whose tumors overexpress B7-H4. Five Prime plans to use this IHC assay in the expansion portion of the ongoing Phase 1 clinical trial of FPA150 to identify patients with advanced or metastatic breast, ovarian, endometrial and bladder cancers whose tumors overexpress B7-H4.
Financial terms:
- Financial terms of the agreement were not disclosed.
Latest news:
Is general: Yes
